reports
- Hendra Lau
EURGBP Perfectly Reacting Lower From Blue Box Area
In this technical blog, we are going to take a look at the past performance of EURGBP 4-Hour Elliott wave Charts that we presented to our members. In which, the decline to 2/14/2024 low took place as an and showed a lower sequence with a bearish right side tag calling for more downside to happen. Therefore, our members knew that selling the bounces in the direction of the right side tag remained the preferred path.
- ABGSC Seafood Research
- Martin Kaland
- Simon Brun
- Hendra Lau
Do Not Miss Buying Opportunities Palantir (PLTR) Should Resume Higher
Palantir Technologies (PLTR), Inc. is a holding company, which engages in the development of data integration and software solutions. It operates through the Commercial and Government segments. The firm offers automotive, financial compliance, legal intelligence, mergers and acquisitions solutions.
Array and DNV Release Report on Solar Tracker Wind Stow Strategies’ En...
Array and DNV Release Report on Solar Tracker Wind Stow Strategies’ Energy Impact New evidence sheds light on benefits of Array’s patented, safe, passive wind stow technology ALBUQUERQUE, N.M., May 06, 2024 (GLOBE NEWSWIRE) -- Array Technologies (NASDAQ: ARRY), a leading provider of solar tracking solutions, confirmed in a new study that its safe, passive wind stow solution can significantly optimize energy production. Array collaborated with DNV Energy USA (DNV) to publish a comprehensive report titled “Energy Impact of Different Solar Tracker Wind Stow Strategies,” outlining the benef...
T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024. Recent Financial and Operational Highlights Achieved first quarter 2024 sepsis product revenue of $2.1 m...
T2 Biosystems Announces Commercial Expansion Through Middle East Distr...
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Qatar. Under the terms of the agreement, T2 Biosystems will sell T2Dx® Instruments, the T2Bacteria...
Mueller Water Products Reports 2024 Second Quarter Results
Mueller Water Products Reports 2024 Second Quarter Results Increased Net Sales 6.2 percent to $353.4 Million Reported Net Income per Diluted Share of $0.28 Achieved Record Adjusted Net Income per Diluted Share of $0.30 Raises Annual Guidance for Net Sales and Adjusted EBITDA Company Also Today Announced Update on Leadership Team and Board Refreshment ATLANTA, May 06, 2024 (GLOBE NEWSWIRE) -- Mueller Water Products, Inc. (NYSE: MWA) announced financial results for its 2024 second quarter ended March 31, 2024. In the second quarter of 2024, the Company: Delivered net sa...
Pineapple Energy to Release First Quarter 2024 Results, Host Conferenc...
Pineapple Energy to Release First Quarter 2024 Results, Host Conference Call on May 10 MINNETONKA, Minn., May 06, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced that management will host a conference call for investors and analysts on Friday, May 10 at 8:30am ET to discuss the company’s first quarter 2024 financial results. The company plans to provide a press release reporting its results on the Investor Relations section of its website at after the close ...
Cabot Corp Reports Second Quarter Fiscal 2024 Results
BOSTON--(BUSINESS WIRE)-- (NYSE: CBT) today announced results for its second quarter of fiscal year 2024. Key Highlights Diluted EPS of $1.49 and adjusted EPS of $1.78, which represents a 34% increase in Adjusted EPS as compared to the same quarter in the prior year Reinforcement Materials segment EBIT of $149 million; up 22% compared to the same quarter in the prior year Performance Chemicals segment EBIT of $31 million; up 11% compared to the same quarter in the prior year Cash Flows from Operations of $176 million in the second fiscal quarter supported the return of $47 milli...
The Metals Company Announces First Quarter 2024 Corporate Update Confe...
The Metals Company Announces First Quarter 2024 Corporate Update Conference Call for Monday, May 13, 2024 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- The Metals Company (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today announced that it will host a conference call on Monday, May 13, 2024, to provide an update on first quarter financial results and recent corporate developments. First Quarter 2024 Conference Call Details Date: Monday, May 13, 2024 Time: 4:30 p.m. ET Audio-only Dial-in: Virtual webcast w...
- Hendra Lau
SPDR Energy Select Sector ( $XLE) Found Buyers at the Blue Box Area as...
Hello everyone. In today’s article, we will look at the past performance of the 4H Hour Elliott Wave chart of SPDR Energy Select Sector ($XLE). The rally from 1.18.2024 low at $78.98 unfolded as 5 waves impulse. We expected the pullback to unfold in 3 swings and find buyers again.
Coty Reports Strong Results Ahead of Beauty Market, with Double-Digit ...
NEW YORK--(BUSINESS WIRE)-- Coty Inc. (NYSE: COTY) (Paris:COTY) ("Coty" or "the Company") today announced its results for the third quarter of fiscal year 2024, ended March 31, 2024. The Company's strong above-market sales growth, reported and adjusted operating income growth, and reported and adjusted gross and operating margin expansion in Q3 solidifies nearly four years of Coty reporting results in-line to ahead of expectations. In 3Q24, Coty's net revenues grew 8% on a reported basis and 10% on a LFL basis, with reported and LFL results supported by growth in fragrances, color cosmetics,...
Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights04/30/202471,955,53577,891,229 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, Investor Relations cont...
Day One Reports First Quarter 2024 Financial Results and Corporate Pro...
Day One Reports First Quarter 2024 Financial Results and Corporate Progress OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2024...
Immuneering Recognizes Melanoma Awareness Month
Immuneering Recognizes Melanoma Awareness Month - Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-sta...
Quaint Oak Bancorp, Inc. Announces First Quarter Earnings
Quaint Oak Bancorp, Inc. Announces First Quarter Earnings Southampton, PA, May 06, 2024 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended March 31, 2024 of $873,000, or $0.36 per basic and diluted share, compared to net income of $563,000, or $0.26 per basic and $0.25 per diluted share for the same period in 2023. Robert T. Strong, President and Chief Executive Officer stated, “I am pleased to report that net income for the three months ended March 31, 2024, ...
Information mensuelle relative au nombre total des droits de vote et d...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote30/04/202471 955 53577 891 229 Pour de plus amples informations sur Cellectis, veuillez contacter : Contact média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, ...
Aptose to Report First Quarter 2024 Financial Results and Provide Clin...
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company’s Chief Medical Officer and ...
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024B.Riley Securities 24th Annual Institutional Investor Conference, Beverly Hills, May 22 – 23, 2024Stifel Cross Sector I...
Moody's Ratings assigns Aa1 to Atlanta GA's Series 2024 revenue bonds
Moody's Ratings (Moody's) has assigned a Aa1 to the City of Atlanta and Fulton County Recreation Authority, GA's Revenue Bonds (Multipurpose Golf and Senior Center Project), Series 2024 in an anticipated par amount not to exceed $30 million. The bonds are backed by the City of Atlanta, GA's general ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.